[CAS NO. 1708113-43-2] ACY-1083
PRODUCTS SPECIFICATIONS [1708113-43-2]
DESCRIPTION [1708113-43-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 348.35 |
| Molecular Formula | C17H18F2N4O2 |
| SMILES | FC(CC1)(F)CCC1(NC2=NC=C(C(NO)=O)C=N2)C3=CC=CC=C3 |
1 Publications Citing Use of MCE
Summary
IC50 & Target
|
HDAC6 3 nM (IC 50 ) |
In Vitro
Treatment with ACY-1083 (30 and 300 nM) significantly improves cell viability in a dose-dependent manner [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [2]
| Cell Line: | Mouse hippocampal (HT22) cells |
| Concentration: | 30 and 300 nM |
| Incubation Time: | |
| Result: | Significant improvement in cell viability. |
In Vivo
ACY-1083 (i.p.; 10 mg/kg; for 7 days) effectively relieves Cisplatin-induced mechanical allodynia in C57BL/6J mice
ACY-1083 (oral doses of 3 mg/kg ACY-1083 for 7 days) reverses Paclitaxel-induced mechanical allodynia in adult male SD rats.
Mice dosed with 5 mg/kg ACY-1083 by intraperitoneal (i.p.) injection have a maximum plasma concentration (C
max
) of 936 ng/mL, a half-life (T
1/2
) of 3.5 hours, and a biologically active plasma exposure of 8 hours after dosing.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Adult male C57BL/6J mice of 8-10 weeks of age [1] |
| Dosage: | 3 or 10 mg/kg |
| Administration: | Administered i.p. injection; daily; for 7 days |
| Result: | The 10 mg/kg relieved Cisplatin (2.3 mg/kg)-induced mechanical allodynia, whereas the 3 mg/kg dose did not. |
| Animal Model: | Adult male Sprague Dawley rats [1] |
| Dosage: | 3 mg/kg |
| Administration: | Two daily doses were given orally for 7 days. |
| Result: | Reversed Paclitaxel (6 mg/kg or 12 mg/kg)-induced mechanical allodynia. |
Appearance
Oil
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvent & Solubility
DMSO : 200 mg/mL ( 574.14 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.8707 mL | 14.3534 mL | 28.7068 mL |
| 5 mM | 0.5741 mL | 2.8707 mL | 5.7414 mL |
| 10 mM | 0.2871 mL | 1.4353 mL | 2.8707 mL |
References
- [1] Krukowski K, et al. HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy. Pain. 2017 Jun;158(6):1126-1137.
- [2] Vahagn C Nikolian, et al. Isoform 6-selective histone deacetylase inhibition reduces lesion size and brain swelling following traumatic brain injury and hemorrhagic shock. J Trauma Acute Care Surg. 2019 Feb;86(2):232-239.
